Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II extension study of BIBF 1120 in idiopathic pulmonary fibrosis
2009-013788-21Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Primary endpoint: Decline in forced vital capacity. Started Feb 2010; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2009-013788-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013788-21.